Kidney Failure, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Despite optimal management of diabetic kidney disease (DKD) with intensive glycemic control and administration of agents blocking the renin-angiotensinaldosterone- system, the residual risk for nephropathy progression to end-stage-renal-disease (ESRD) remains high.
|
29792136 |
2019 |
Kidney Failure, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The presumed superiority of renin-angiotensin-aldosterone system (RAAS)-blocking agents over other antihypertensive agents in patients with diabetes to delay development of end-stage kidney disease (ESKD) has recently been challenged.
|
29106631 |
2018 |
Kidney Failure, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this pooled analysis of four prospective studies in CKD patients treated with drugs inhibiting the renin-angiotensin system, we compared the risk of all-cause mortality, fatal and non-fatal cardiovascular (CV) events and end-stage renal disease (ESRD) between patients with (n = 693) and without diabetes (n = 1481) stratified by proteinuria level (<0.15, 0.15-0.49, 0.5-1 and >1 g/day).
|
29509925 |
2018 |
Kidney Failure, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Obesity, whether defined by BMI or BF%, was not associated with a significantly increased risk of ESRD in Cox proportional hazards models that adjusted for age, sex, diabetes mellitus, cardiovascular disease, estimated glomerular filtration rate, urine protein:creatinine ratio, high-sensitivity C-reactive protein, and use of renin-angiotensin-aldosterone system inhibitors or statins, accounting for the competing risk for mortality (subdistribution HR: 1.15; 95% CI: 0.62, 2.14 for BMI-defined obesity and subdistribution HR: 0.84, 95% CI: 0.54, 1.29 for BF%-defined obesity, respectively).
|
30321257 |
2018 |
Kidney Failure, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mid-regional pro-atrial natriuretic peptide (MR-proANP), N-terminal prohormone of brain natriuretic peptide (NT-proBNP), vasopressin (AVP) and copeptin (CT-proAVP), metanephrines and normetanephrines, renin and aldosterone, standard transthoracic echocardiography and diameter of vena cava inferior (VCID) were performed in 20 patients with end stage renal disease (CKD5D) before and after HD and were stratified in residual excretion (RE, less or more 0.5 l) and ultrafiltration rate (UF, less or more 2 l).
|
28558715 |
2017 |
Kidney Failure, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Despite the benefits derived from strict control of glucose and blood pressure, as well as inhibition of renin-angiotensin-aldosterone system, many patients continue to enter into ESRD.
|
28386567 |
2017 |
Kidney Failure, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Despite optimal therapy of diabetic nephropathy with agents blocking the renin-angiotensin-aldosterone system, the residual risk of nephropathy progression to end-stage renal disease (ESRD) remains high.
|
28520568 |
2017 |
Kidney Failure, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
With the realization that lowering blood pressure, including with renin-angiotensin system blockade, failed to reliably prevent end-stage kidney disease, studies now are analyzing longer-term effects of hypertension control on survival in chronic kidney disease.
|
28087008 |
2017 |
Kidney Failure, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The progression to ESRD in patients with obesity and diabetes continues despite widespread use of inhibitors of the renin-angiotensin-aldosterone system (RAAS) along with aggressive blood pressure and glycemic control in these high-risk populations.
|
28341271 |
2017 |
Kidney Failure, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Weight loss, either induced by diet or bariatric surgery, and renin-angiotensin blockers are effective treatments to slow progression, but a significant proportion of cases will develop end-stage renal disease.
|
27414023 |
2017 |
Kidney Failure, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The renin-angiotensin-aldosterone system blockade is central to the current treatment of patients with chronic kidney disease (CKD) for the renoprotective effects aimed to prevent or slow progression to end-stage renal disease (ESRD).
|
25176603 |
2015 |
Kidney Failure, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We conclude that heterozygous substitutions at the AGT M235T and REN A/G(I8-83) loci correlate significantly with ESRD in a north Indian population.
|
25660845 |
2015 |
Kidney Failure, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analysis of genetic factors connected with the renin-angiotensin system that influences the survival of the patients with end-stage kidney disease supports the ongoing search for improved outcomes.
|
25076182 |
2014 |
Kidney Failure, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
A number of genetic variations involved in renin-angiotensin-aldosterone system (RAAS) pathway genes have clinical or physiological impacts on pathogenesis of hypertension-induced ESRD in ADPKD.
|
25001132 |
2014 |
Kidney Failure, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The evidence for a beneficial renoprotective effect of renin-angiotensin-aldosterone system (RAAS) blockade by angiotensin-converting enzyme (ACE) inhibition and/or angiotensin receptor blockers (ARBs) is well established in AS and recent evidence has shown that it can significantly delay the time to onset of renal replacement therapy and ESKD.
|
22903660 |
2013 |
Kidney Failure, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Renin-angiotensin system (RAS) blockade is the standard of care; however, a significant proportion of patients progress to ESRD.
|
21144773 |
2012 |
Kidney Failure, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients treated with renin-angiotensin system blockade or calcium channel blockers during follow-up had significantly later onset of ESRD by 4.3 years and 2.1 years, respectively.
|
22297678 |
2012 |
Kidney Failure, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphisms of the renin-angiotensin-aldosterone system in Chinese patients with end-stage renal disease secondary to IgA nephropathy.
|
21163122 |
2010 |
Kidney Failure, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Renin-angiotensin system polymorphisms: a risk factor for progression to end-stage renal disease in vesicoureteral reflux patients.
|
19288324 |
2009 |
Kidney Failure, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The renin-angiotensin system (RAS) plays an important role in progression of chronic renal disease.
|
18454324 |
2009 |
Kidney Failure, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Dominant renin gene mutations associated with early-onset hyperuricemia, anemia, and chronic kidney failure.
|
19664745 |
2009 |
Kidney Failure, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We examined an association of the three renin-angiotensin system (RAS) gene polymorphisms with renal disease and progression to ESRD in dialyzed patients.
|
16384824 |
2006 |
Kidney Failure, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The renin-angiotensin system (RAS) plays important roles progression of chronic renal disease.
|
15659127 |
2005 |
Kidney Failure, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The role of interaction of polymorphisms in the Renin-Angiotensin-System (RAS) with angiotensin converting enzyme (ACE) or angiotensin receptor (AGTR1) inhibitors (RAS inhibitors) is unknown, as is the role of such therapy in end stage renal disease (ESRD) patients.
|
15946912 |
2005 |
Kidney Failure, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, this polymorphism may interact with other polymorphisms within the renin-angiotensin system, leading to high risk of ESRD.
|
16088846 |
2005 |